A Phase I/IIa Clinical Trial to Evaluate the Safety, Tolerability and Pharmacokinetics of TST001 Administered as Monotherapy or in Combination With Nivolumab or Standard of Care in Patients With Locally Advanced or Metastatic Solid Tumors
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 150
- 试验地点
- 18
- 主要终点
- Participant Safety as characterized by frequency and severity of adverse events
研究概览
简要总结
This is an open label Phase I/IIa, First in Human trial of TST001, a recombinant humanized anti-Claudin 18.2 (CLDN18.2) IgG1 monoclonal antibody as monotherapy or in combination with nivolumab or standard of care. It is being tested against advanced and/or metastatic solid tumors including gastric, gastroesophageal junction, pancreatic cancers.
详细描述
Part A of the trial will consist of two cohorts, one dosed every 2 weeks and one dosed every 3 weeks in a standard 3+3 design. Part A is the dose finding portion of the trial.
18 to 36 participants will be enrolled.
Part B consists of 3 cohorts:
Cohort A is for patients with previously untreated, unresectable, locally advanced or metastatic GC/GEJ adenocarcinoma. Patients will receive TST001 at 2mg/kg or 4mg/kg Q2W plus Nivolumab and mFOLFOX6. Alternative allocation of patients between the 2 doses will be performed. The first 6 patients at each dose level as the lead-in phase will not be selected on the basis of their tumor's CLDN18.2 expression. Approximately 12-42 patients will be enrolled in Cohort A.
Cohort B is for patients with GC/GEJ adenocarcinoma who have radiologically progressed following one or two prior systemic therapies. Patient will receive TST001 plus Nivolumab. No selection based on CLDN18.2 expression will be required for the safety run-in (3-6 patients). Patients with CLDN18.2 expression in tumor tissue tested by the central laboratory will be enrolled in the expansion phase. Safety run-in phase will follow 3+3 rule with two dose levels, TST001 3mg/kg and 6mg/kg Q3W combined with nivolumab. Approximately 30 patients will be enrolled in Cohort B including the patients in the safety run-in phase.
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Male or female ≥ 18 years.
- •Patients with histologically or cytologically confirmed, locally advanced or metastatic solid tumors.
- •Part A only:
- •* Patients must be: a) progressed after standard therapies, b) intolerant of standard therapies, or c) with a tumor type without standard therapy.
- •Part B only:
- •Cohort A: Patients with previously untreated, unresectable, locally advanced or metastatic GC/GEJ adenocarcinoma; prior adjuvant or neoadjuvant therapy are allowed only if disease progressed or recurred at least 6 months after completion of these treatments. Patients may have received one infusion of mFOLFOX6 plus nivolumab during the screening period.
- •Cohort B: Patients with GC/GEJ adenocarcinoma who have radiologically progressed following one or two prior systemic therapies; adjuvant or neoadjuvant therapy could be regarded as one line of therapy only if disease progressed or recurred during these treatments or within 6 months or less after completion of these treatments.
- •Cohort C: Patients with previously untreated, unresectable, locally advanced or metastatic histologically confirmed pancreatic adenocarcinoma; prior adjuvant or neoadjuvant therapy are allowed only if disease progressed or recurred at least 6 months after completion of these treatments. Patients may have received up to 2 infusions of Gemcitabine + albumin-bound paclitaxel (with one week between each infusion) during the screening period.
- •Eastern Cooperative Oncology Group Performance Status (ECOG PS): 0-1 .
- •Patients with adequate cardiac, liver, renal function, etc.
- •Exclusion Criteria
- •Symptomatic central nervous system metastases.
- •Prior treatment with any CLDN18.2 target agents
- •Allergy or sensitivity to TST001 or known allergies to comparable drugs
- •Documented history of multiple other allergies requiring interventions
- •Severe cardiovascular disease, including CVA, TIA, myocardial infarction, or unstable angina, NYHA class III or IV heart failure or uncontrolled arrhythmia within 6 months of study entry, severe QTc prolongation, concomitant risks for QTc prolongation.
- •Concurrent malignancy within 5 years prior to entry except adequately treated certain types of cancer
- •Active and clinically significant infections, known uncontrolled infections with hepatitis B, hepatitis C, known human immunodeficiency virus with acquired immunodeficiency syndrome related illness
- •Any condition that the investigator or primary physician believes may not be appropriate for participating in the study.
- •Other protocol-defined Inclusion/Exclusion Criteria could apply.
排除标准
- 未提供
研究组 & 干预措施
Part A Q2W
Dosed every 2 weeks IV with TST001, starting dose is 1 mg/kg, multiple dose levels will be tested.
干预措施: TST001 (Drug)
Part A Q3W
Dosed every 3 weeks IV with TST001, starting dose is 3 mg/kg, and multiple dose levels will be tested.
干预措施: TST001 (Drug)
Part B Cohort A
Patients with previously untreated, unresectable, locally advanced or metastatic GC/GEJ adenocarcinoma.
干预措施: TST001 (Drug)
Part B Cohort A
Patients with previously untreated, unresectable, locally advanced or metastatic GC/GEJ adenocarcinoma.
干预措施: mFOLFOX6 (Drug)
Part B Cohort A
Patients with previously untreated, unresectable, locally advanced or metastatic GC/GEJ adenocarcinoma.
干预措施: Nivolumab Injection [Opdivo] (Drug)
Part B Cohort B
Patients with GC/GEJ adenocarcinoma who have radiologically progressed following one or two prior systemic therapies.
干预措施: TST001 (Drug)
Part B Cohort B
Patients with GC/GEJ adenocarcinoma who have radiologically progressed following one or two prior systemic therapies.
干预措施: Nivolumab Injection [Opdivo] (Drug)
Part B Cohort C
Patients with previously untreated, unresectable, locally advanced or metastatic histologically confirmed pancreatic adenocarcinoma.
干预措施: TST001 (Drug)
Part B Cohort C
Patients with previously untreated, unresectable, locally advanced or metastatic histologically confirmed pancreatic adenocarcinoma.
干预措施: Gemcitabine (Drug)
Part B Cohort C
Patients with previously untreated, unresectable, locally advanced or metastatic histologically confirmed pancreatic adenocarcinoma.
干预措施: Albumin-Bound Paclitaxel (Drug)
结局指标
主要结局
Participant Safety as characterized by frequency and severity of adverse events
时间窗: up to 100 days following last dose
Characterization of TST001 safety profile including frequency and severity of adverse events that are related to treatment.
Maximum Tolerated Dose (MTD or Recommended Phase 2 Dose (RP2D)
时间窗: up to 100 days following last dose
As measured by number of participants experiencing dose related toxicity (DLT) in each escalating cohort
Participant Safety and Tolerability of TST001 in combination with Nivolumab as characterized by frequency and severity of adverse events
时间窗: Up to 100 days following last dose
Characterization of TST001 + Nivolumab safety profile including frequency and severity of adverse events that are related to treatment.
Participant Safety and Tolerability of TST001 in combination with Nivolumab and mFOLFOX6 as characterized by frequency and severity of adverse events
时间窗: Up to 100 days following last dose
Characterization of TST001 + Nivolumab + mFOLFOX6 safety profile including frequency and severity of adverse events that are related to treatment.
Participant Safety and Tolerability of TST001 in combination with gemcitabine and albumin-bound paclitaxel as characterized by frequency and severity of adverse events
时间窗: Up to 100 days following last dose
Characterization of TST001 + Gemcitabine + albumin-bound paclitaxel safety profile including frequency and severity of adverse events that are related to treatment.
次要结局
- Immunogenicity(up to 30 days following last dose)
- Objective response rate (ORR)(up to 24 months, until disease progression or start of another anti-cancer therapy)
- Duration of Response (DOR)(up to 24 months, until disease progression or start of another anti-cancer therapy)
- Progression free survival (PFS)(up to 24 months, until disease progression or start of another anti-cancer therapy)
- PK parameters(Up to 30 days following last dose)
- PK(Up to 30 days following last dose)